Study of patients who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just ...

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections.Please watch the video at Investors.com - S&P 500 Giants Report Earnings. Will Megacap Results Sustain ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...

A new study by researchers at Brigham and Women's Hospital in collaboration with researchers at Harvard T.H. Chan School of ...

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...